149 related articles for article (PubMed ID: 9786595)
1. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
[TBL] [Abstract][Full Text] [Related]
2. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer.
Sakata H; Murakami S; Hirayama R
Int J Clin Oncol; 2002 Oct; 7(5):312-7. PubMed ID: 12402066
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of c-erbb-2 correlate with advanced stage and liver metastasis in colorectal cancer.
Polychronidis AC; Tsaroucha AK; Anagnostoulis SK; Efstathiou EE; Georgiadis PG; Simopoulos CE
Folia Med (Plovdiv); 2003; 45(2):12-6. PubMed ID: 12943051
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer.
Murakami S; Sakata H; Tsuji Y; Okubo K; Hamada S; Hirayama R
Dig Surg; 2002; 19(1):9-13; discussion 14. PubMed ID: 11961349
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble interleukin-2 receptor in colorectal cancer.
Murakami S; Satomi A; Ishida K; Murai H; Okamura Y
Acta Oncol; 1994; 33(1):19-21. PubMed ID: 8142118
[TBL] [Abstract][Full Text] [Related]
7. Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis.
Haraguchi M; Komuta K; Akashi A; Matsuzaki S; Furui J; Kanematsu T
Oncol Rep; 2002; 9(1):159-65. PubMed ID: 11748475
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
9. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients.
Ito H; Miki C
Scand J Gastroenterol; 1999 Nov; 34(11):1139-43. PubMed ID: 10582766
[TBL] [Abstract][Full Text] [Related]
10. The presence of interleukin-2 receptor alpha in the serum of colorectal cancer patients is unlikely to result only from T cell up-regulation.
Huang A; Quinn H; Glover C; Henderson DC; Allen-Mersh TG
Cancer Immunol Immunother; 2002 Mar; 51(1):53-7. PubMed ID: 11845260
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients.
Iwagaki H; Hizuta A; Tanaka N
Scand J Gastroenterol; 1997 Jun; 32(6):577-81. PubMed ID: 9200291
[TBL] [Abstract][Full Text] [Related]
12. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor.
Kaminska J; Nowacki MP; Kowalska M; Rysinska A; Chwalinski M; Fuksiewicz M; Michalski W; Chechlinska M
Tumour Biol; 2005; 26(4):186-94. PubMed ID: 16006772
[TBL] [Abstract][Full Text] [Related]
15. Paired tumor marker of soluble E-selectin and its ligand sialyl Lewis A in colorectal cancer.
Ito K; Ye CL; Hibi K; Mitsuoka C; Kannagi R; Hidemura K; Ando H; Kasai Y; Akiyama S; Nakao A
J Gastroenterol; 2001 Dec; 36(12):823-9. PubMed ID: 11777210
[TBL] [Abstract][Full Text] [Related]
16. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients.
Matsushita K; Toiyama Y; Tanaka K; Saigusa S; Hiro J; Uchida K; Inoue Y; Kusunoki M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S518-27. PubMed ID: 21845497
[TBL] [Abstract][Full Text] [Related]
17. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
[TBL] [Abstract][Full Text] [Related]
18. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
Murakami S; Satomi A; Ishida K; Murai H; Matsuki M; Hashimoto T
Cancer; 1994 Nov; 74(10):2745-8. PubMed ID: 7525035
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
20. Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients.
Saigusa S; Tanaka K; Inoue Y; Toiyama Y; Okugawa Y; Iwata T; Mohri Y; Kusunoki M
Int Surg; 2014; 99(3):223-9. PubMed ID: 24833143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
